Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Delhi
Clinical trial register · India

Clinical Trials in Delhi, 2026

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1120 matching records held by the registry are in this view. Synced 07 Nov 2026, 03:16 UTC
1120
Studies in scope
all four open statuses
608
Recruiting now
open to new participants
218
Lead sponsors
across recruiting studies
Top sites
Kolkata 54 Delhi 41 Bangalore 41 New Delhi 39 Hyderabad 37
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca41 Novo Nordisk A/S6 Bristol-Myers Squibb6 Novartis Pharmaceuticals3 All India Institute of Medical Sciences3 Clear sponsor filter
Site location
Kolkata54 Delhi41 Bangalore41 New Delhi39 Hyderabad37
All 80 locations
Target enrolment
to

Trials with a site in Delhi

41 of 1120 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Recruiting
AstraZeneca
Phase 3
1,330
Ansārinagar, Bangalore, Delhi, Kannur, Nagpur, New Delhi, Vadodara
2026-09-15
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Belagavi, Calicut, Coimbatore, Dehradun, Delhi, Hyderabad, Jaipur, Kanpur
2026-08-24
Recruiting
AstraZeneca
Phase 3
7,000
Aligarh, Bangalore, Belagavi, Bhubaneswar, Calicut, Chennai, Dehradun, Delhi
2026-08-21
Recruiting
AstraZeneca
Phase 3
900
Aligarh, Belagavi, Belgavi, Calicut, Chennai, Coimbatore, Delhi, Guntur
2026-07-06
Recruiting
AstraZeneca
Phase 3
4,500
Bangalore, Belagavi, Bikaner, Delhi, Guntur, Hyderabad, Jaipur, Jodhpur
2026-06-29
Recruiting
AstraZeneca
Phase 3
1,100
Bhubaneswar, Chennai, Delhi, Dhanvantari Nagar, Kolkata, Nagpur, Nashik, Surat
2025-12-29
Recruiting
AstraZeneca
Phase 3
1,100
Delhi, Hyderabad, Kolhāpur, Kolkata, Mumbai, Nashik, Surat
2025-12-04
Active, closed
AstraZeneca
Phase 3
212
Belagavi, Delhi, Hyderabad, Kolkata, Mumbai
2025-08-07
Recruiting
AstraZeneca
Phase 3
700
Ansārinagar, Babgalore, Calicut, Delhi, Hyderabad, Kannur, Kanpur, Mumbai
2025-08-06
Recruiting
AstraZeneca
Phase 2
987
Belagavi, Coimbatore, Dehradun, Delhi, Dwārka, Hyderabad, Kochi, Mumbai
2025-06-27
Recruiting
AstraZeneca
Phase 3
1,220
Ahmedabad, Bangalore, Binnāguri, Dehradun, Delhi, Hyderabad, Mumbai, Nashik
2025-05-06
Recruiting
AstraZeneca
Phase 2
540
Belagavi, Coimbatore, Dehradun, Delhi, Faridabad, Gūrgaon, Kochi, Lucknow
2025-03-26
Recruiting
AstraZeneca
Phase 3
990
Ahmedabad, Aligarh, Belagavi, Coimbatore, Dehradun, Delhi, Dwārka, Faridabad
2025-03-18
Recruiting
AstraZeneca
Phase 3
11,300
Ahmedabad, Ajmer, Bangalore, Belagavi, Dehradun, Delhi, Gūrgaon, Hyderabad
2025-03-14
Recruiting
AstraZeneca
Phase 3
840
Ansārinagar, Bangalore, Delhi, Hyderabad, Kolkata, Mumbai, Varanasi
2025-03-01
Active, closed
AstraZeneca
Phase 4
100
Bangalore, Delhi, Kochi, Mumbai, New Delhi, Pune, Varanasi
2025-01-02
Recruiting
AstraZeneca
Phase 3
1,160
Calicut, Delhi, Gūrgaon, Kolkata, Madurai, Mumbai, Nashik, New Delhi
2024-11-27
Recruiting
AstraZeneca
Phase 3
1,160
Calicut, Delhi, Gūrgaon, Kolkata, Madurai, Mumbai, Nagpur, Nashik
2024-11-18
Recruiting
AstraZeneca
Phase 3
620
Dehradun, Delhi, Kanpur, Kolkata, Mumbai, Vadodara, Varanasi
2024-08-12
Recruiting
AstraZeneca
Phase 3
1,018
Delhi, Gurugram, Kolkata, Nashik, Surat, Thiruvananthapuram
2024-08-07
Recruiting
AstraZeneca
Phase 3
788
Delhi, Kolkata, Lucknow, Mumbai, Mysuru, Nagpur, Nashik, New Delhi
2024-08-01
Recruiting
AstraZeneca
Phase 3
240
Ahmedabad, Bangalore, Dehradun, Delhi, Gurugram, Hyderabad, Kolkata, Lucknow
2024-06-20
Recruiting
AstraZeneca
Phase 3
582
Bangalore, Delhi, Hyderabad, Kolkata, Mysuru, Nagpur, Nashik, New Delhi
2024-04-29
Recruiting
AstraZeneca
Phase 3
3,850
Ahmedabad, Ajmer, Amritsar, Bangalore, Belagavi, Coimbatore, Dehradun, Delhi
2024-04-12
Recruiting
AstraZeneca
Phase 3
5,250
Ahmedabad, Aligarh, Belagavi, Calicut, Chandigarh, Dehradun, Delhi, Dwārka
2024-02-21
Active, closed
AstraZeneca
Phase 3
760
Delhi, Kolkata, Mumbai, Mysuru, New Delhi, Varanasi
2023-12-04
Active, closed
AstraZeneca
Phase 3
1,902
Bengaluru, Delhi, Kolkata, Marg Jaipur, Nagpur, Nashik, Thiruvananthapuram, Vadodara
2023-11-14
Active, closed
AstraZeneca
Phase 3
314
Ahmedabad, Delhi, Gurugram, Hyderabad, Kolkata, Mumbai, Mysuru, New Delhi
2023-11-08
Active, closed
AstraZeneca
Phase 3
1,835
Bangalore, Belagavi, Delhi, Nadiād, New Delhi
2023-11-07
Active, closed
AstraZeneca
Phase 3
5,511
Ansārinagar, Bangalore, Dehradun, Delhi, Kolkata, Kozhikode, Mumbai, Mysuru
2023-10-05
Active, closed
AstraZeneca
Phase 3
1,350
Calicut, Delhi, Jaipur, Kolkata, Madurai, Puducherry
2022-12-29
Active, closed
AstraZeneca
Phase 3
760
Ahmedabad, Bangalore, Delhi, Hyderabad, Jaipur, Kolkata, Mumbai, New Delhi
2022-03-28
Active, closed
AstraZeneca
Phase 3
791
Ahmedabad, Bangalore, Delhi, Howrah, Hyderabad, Jaipur, Kolkata, Marg Jaipur
2022-02-18
Active, closed
AstraZeneca
Phase 3
363
Ahmedabad, Dehradun, Delhi, Hyderabad, Kolkata, Nadiād, Pune, Secunderabad
2022-02-15
Active, closed
AstraZeneca
Phase 3
454
Bangalore, Delhi, Hyderabad, Mumbai, Nashik
2021-10-28
Active, closed
AstraZeneca
Phase 3
1,371
Ahmedabad, Calicut, Delhi, Faridabad, Gūrgaon, Karamsad, Kolkata, Madurai
2021-01-28
Active, closed
AstraZeneca
Phase 1/2
245
Delhi, Gūrgaon, Madurai, Mumbai
2020-12-28
Active, closed
AstraZeneca
Phase 2
30
Delhi, Mumbai
2020-09-28
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
477
Delhi, Gūrgaon, Kolkata, Mumbai
2020-08-18
Active, closed
AstraZeneca
Phase 3
134
Ahmedabad, Ajmer, Delhi
2020-07-20
Active, closed
AstraZeneca
Phase 3
1,012
Ahmedabad, Bangalore, Delhi, Faridabad, Kanpur, Kolkata, Madurai, Manipal
2020-07-13
Rows per page Showing 1–41 of 41
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 November 2026. https://priyalifescience.com/clinical-trials-india/city/delhi

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in India and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,120 studies in total at the last sync on 07 Nov 2026, 03:16 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 41 of those studies with a site in Delhi that also match the filters currently applied.

How many clinical trials are recruiting in Delhi?

23 of the 41 studies on this page are recruiting new participants as of the 07 Nov 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 18 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Delhi), 41 studies
PhaseStudiesRecruitingShare
Phase 3352185.4%
Phase 2429.8%
Phase 1/2102.4%
Phase 4102.4%

Most active sponsors

Lead sponsors with the most studies (Delhi)
Lead sponsorStudiesRecruiting
AstraZeneca4123
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.